Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Assets (2019 - 2025)

Legend Biotech filings provide 7 years of Assets readings, the most recent being $1.7 billion for Q4 2025.

  • On a quarterly basis, Assets rose 3.8% to $1.7 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $1.7 billion, a 3.8% increase, with the full-year FY2025 number at $1.7 billion, up 3.8% from a year prior.
  • Assets hit $1.7 billion in Q4 2025 for Legend Biotech, up from $1.7 billion in the prior quarter.
  • In the past five years, Assets ranged from a high of $615.3 billion in Q1 2021 to a low of $813.8 million in Q3 2021.
  • Median Assets over the past 5 years was $1.7 billion (2025), compared with a mean of $35.6 billion.
  • The widest YoY moves for Assets: up 55.03% in 2021, down 99.89% in 2021.
  • Legend Biotech's Assets stood at $1.1 billion in 2021, then grew by 18.89% to $1.3 billion in 2022, then skyrocketed by 38.89% to $1.8 billion in 2023, then fell by 9.65% to $1.7 billion in 2024, then rose by 3.8% to $1.7 billion in 2025.
  • The last three reported values for Assets were $1.7 billion (Q4 2025), $1.7 billion (Q3 2025), and $1.7 billion (Q2 2025) per Business Quant data.